Research

Hormonal

Combining GIPR agonism or antagonism with GLP-1 R agonism produces synergistic weight loss in preclinical models, whereas GIPR signaling is not required for this synergy in humans.

Combining GIP and GLP-1 hormones (as seen in drugs like tirzepatide) is more effective for weight loss than GLP-1 alone, likely because they work together synergistically. However, the exact way this works in humans is still debated, as animal studies do not perfectly predict human biology.

ModerateQualifiesMEDIUM confidence
Multiple publications from various groups have reported synergy between GLP-1 R agonists and GIPR agonists where the observed weight loss seen by combining GLP-1 R agonists and GIPR agonists is greater than the sum of the weight loss produced by either agent alone... While it is clear that GIPR signaling is necessary for the additional benefits of GLP-1 R agonists/GIPR agonists or antagonists in preclinical models, this is more controversial in man.
Iona Davies et al. · Expert Opinion on Drug Discovery · 2023

Why this rating

Strong preclinical data exists, but human physiological studies contradict the mechanism.

Source

Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss

Iona Davies et al. · Expert Opinion on Drug Discovery · 2023

DOI 10.1080/17460441.2023.2203911

narrative_reviewCited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →